<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03412903</url>
  </required_header>
  <id_info>
    <org_study_id>17-137</org_study_id>
    <secondary_id>EK 230/17</secondary_id>
    <nct_id>NCT03412903</nct_id>
  </id_info>
  <brief_title>The Pharmacist in the Acute Geriatric Inpatient Treatment Team</brief_title>
  <acronym>AGITATE</acronym>
  <official_title>The Pharmacist in the Acute Geriatric Inpatient Treatment Team - Impact on Re-hospitalization and Trans-sectoral Communication</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Prof. Dr. med. Cornelius Bollheimer</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>RWTH Aachen University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial investigates the effects of a comprehensive pharmaceutical assessment in an acute
      care geriatric hospital on the number of hospital readmissions and patient's days spent at
      home.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Drug-related problems are common in elderly patients. These problems can not only be regarded
      from a medical or economical point of view (i.e. hospitalization, drug related deaths, longer
      hospital stays and increased healthcare costs) but also from a patient centered perspective:
      Drug therapy may not be sufficiently explained by health care practitioners, patients might
      suffer from side effects, the number of different medications could be too large and their
      intake schedule too difficult, all of this leading to a reduced adherence. In addition,
      medication histories are rarely accurate in older patients and doctor's letters do not always
      meet the requirements of a complex drug therapy. At the transition from inpatient to
      outpatient treatment this can lead to a significant loss of information and subsequently
      cause patient harm.

      In Germany, clinical, ward-based pharmacists are not yet established in contrast to other
      countries (i.e. Great Britain, Canada and Australia). However, the implementation of a
      clinical pharmacist may particularly address the problems described above. The present study
      therefore describes the implementation of a comprehensive pharmaceutical assessment in an
      acute care geriatric hospital.

      The above mentioned pharmaceutical assessment consists of the following steps:

      First, the pharmacist will obtain the patient's medication history following the protocol of
      &quot;best possible medication history&quot; (WHO). Furthermore, he will ascertain the patient's
      adherence to his/her drug regime. With the information obtained, he will then carry out a
      thorough medication review (regarding interactions, contraindications, suitability for the
      elderly, dosage regimes, etc.) in order to develop a suggestion for the best possible drug
      regime, which is discussed with the treating physician. In addition, he will also observe
      possible side effects and provide information on the background and significance of every
      single drug to the patient and/or his/her care-giver. Furthermore, the handling of difficult
      devices (i.e. insulin pens, inhalators and transdermal therapeutic systems) will be
      individually explained. Finally, the pharmacist will prepare a distinctive paragraph in the
      medical discharge report in which he explains the changes in the medication regime during the
      inpatient period to the general practitioner and will also elaborate possible interactions
      and problems concerning the patient's medication (pharmaceutical council).

      The main outcome to be evaluated will be the number of hospital readmissions and drug related
      hospital readmissions within six months after discharge (recorded at one, three and six
      months). The secondary outcome will be the days spent at home (also recorded at one, three
      and six months), time to readmission, changes in medication within six months and the
      acceptance of the supposed medication regime by the general practitioner (GP).

      The study will be conducted as a before and after comparison in which the steps described
      above will be implemented successively: In the first phase (140 patients planned for an
      observation period of eight months), patients will receive standard care and the pharmacist
      will only obtain the medication history shortly after admission. Results and discrepancies
      will be discussed with the attending physician of the hospital. After discharge, described
      outcomes will be documented. In the second phase (140 patients planned for an observation
      period of eight months), the pharmacist will conduct all of the activities described above.
      The outcomes will be documented as in phase one.

      We expect that the comprehensive pharmaceutical assessment in the second phase will lead to a
      better coordination regarding the medication regime, enhance the patient's knowledge of their
      medication, thus improving their adherence to the therapy and that the pharmaceutical council
      will ensure a better trans-sectoral communication to the GP with a higher acceptance of the
      supposed drug regime in the doctor's letter. All these improvements combined might reduce
      hospital readmissions and increase the patient's days spent at home.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 22, 2018</start_date>
  <completion_date type="Anticipated">January 2020</completion_date>
  <primary_completion_date type="Anticipated">January 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Drug related re-hospitalization</measure>
    <time_frame>6 months</time_frame>
    <description>Number of re-hospitalizations with causal relation to one or more medicinal products, to examine the potential effect of an advising pharmacist</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall re-hospitalization</measure>
    <time_frame>6 months</time_frame>
    <description>Overall number of re-hospitalizations within the observational period per patient</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days spent at home</measure>
    <time_frame>6 months</time_frame>
    <description>Number of days within the observational period not spent in a hospital, short-term care facility, rehabilitation centre, day-care hospital, emergency department or other medical facilities</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Period of time until the potential re-hospitalization into the inpatient sector</measure>
    <time_frame>6 months</time_frame>
    <description>Time between the discharge and a potential re-hospitalization per patient</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acceptance of the recommended medication plan by the further treating primary care physicians</measure>
    <time_frame>6 months</time_frame>
    <description>Adoption of the medication plan, recommended in the doctor's letter, by the further treating primary care physicians</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time required for the pharmacists support</measure>
    <time_frame>6 months</time_frame>
    <description>Expenditure of time, required for the pharmacists support, per patient within the implementation group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Completeness of the pharmaceutical anamnesis in the course of the inpatient admission</measure>
    <time_frame>6 months</time_frame>
    <description>Comparison between the pharmaceutical anamnesis conducted by the doctor and the pharmacist, respectively</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the clinical relevance of the medicinal products, which were not assessed by the doctors</measure>
    <time_frame>6 months</time_frame>
    <description>The evaluation will be conducted by an interdisciplinary group using the focus group method.</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">310</enrollment>
  <condition>Pharmacists in Geriatric Health Services</condition>
  <condition>Conditions Unspecified</condition>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <description>First observational period: Standard care without an advising pharmacist, 140 patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Implementation group</arm_group_label>
    <description>Second observational period: Standard care with an advising pharmacist, 140 patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Learning success group</arm_group_label>
    <description>Second observational period: Standard care without an advising pharmacist, 30 patients</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients admitted to the clinic for internal medicine and geriatrics of the Franziskus
        Hospital Aachen (chair of geriatrics and geriatric medicine of the RWTH Aachen University)
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Geriatric complex treatment (Operation and procedure code (German: &quot;Operationen- und
             Prozedurenschl√ºssel&quot;, OPS) 8-550)

          -  In-patient stay for at least 7 days

          -  Written informed consent of the patient or the legal representative

          -  Existing concomitant drug therapy at the time of the inpatient admission

        Exclusion Criteria:

          -  Patients, that were already included in the study beforehand

          -  Patients classified as terminally ill by the medical staff

          -  Patients, that are incapable to give their informed consent and who do not have a
             legal representative
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>70 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cornelius Bollheimer, Prof. Dr.</last_name>
    <role>Study Director</role>
    <affiliation>University Hospital RWTH Aachen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mathias Freitag</last_name>
    <phone>+49241 7501116</phone>
    <email>mfreitag@ukaachen.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Albrecht Eisert, Dr.</last_name>
    <phone>+49241 8080063</phone>
    <email>aeisert@ukaachen.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Franziskushospital</name>
      <address>
        <city>Aachen</city>
        <state>Northrheinwestfalia</state>
        <zip>52074</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mathias Freitag</last_name>
      <phone>+49241 7501116</phone>
      <email>mfreitag@ukaachen.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 19, 2018</study_first_submitted>
  <study_first_submitted_qc>January 19, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 29, 2018</study_first_posted>
  <last_update_submitted>February 14, 2018</last_update_submitted>
  <last_update_submitted_qc>February 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 15, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>RWTH Aachen University</investigator_affiliation>
    <investigator_full_name>Prof. Dr. med. Cornelius Bollheimer</investigator_full_name>
    <investigator_title>Univ.-Prof. Dr. med., Klinikdirektor</investigator_title>
  </responsible_party>
  <keyword>Acute geriatric treatment</keyword>
  <keyword>Inpatient treatment team</keyword>
  <keyword>Elderly</keyword>
  <keyword>Pharmacist</keyword>
  <keyword>Comprehensive pharmaceutical assessment</keyword>
  <keyword>Medication history</keyword>
  <keyword>Medication reconciliation</keyword>
  <keyword>Adherence</keyword>
  <keyword>Medication therapy management</keyword>
  <keyword>Pharmaceutical consultation</keyword>
  <keyword>Drug-Related Side Effects and Adverse Reactions</keyword>
  <keyword>Drug interactions</keyword>
  <keyword>Pharmaceutical Council</keyword>
  <keyword>Drug regime acceptance</keyword>
  <keyword>Patient Care Team</keyword>
  <keyword>Hospital Pharmacy Service</keyword>
  <keyword>Polypharmacy</keyword>
  <keyword>Hospitalization</keyword>
  <keyword>Pharmaceutical Services</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

